Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A2102 vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
NCT07418749Phase 3Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of SHR-A2102 in Cervical Cancer (CC), sponsored by Suzhou Suncadia Biopharmaceutical. Started Mar 2026; status: recruiting.
02
Drugs
SHR-A2102
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT07418749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07418749.